Top

Published in:

Open Access 01-12-2015 | Review

MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown

Authors: Maria Braoudaki, George I Lambrou

Published in: Journal of Hematology & Oncology | Issue 1/2015

Abstract

MicroRNAs (miRNAs) are endogenous short non-coding RNAs that repress post-transcriptional regulation of gene expression, while embryonal central nervous system tumors are the foremost cause of mortality in children suffering from a neoplasm. MiRNAs and their regulatory mechanisms are new to understand, while pediatric CNS tumors are difficult to comprehend. Therefore, identification of the link between them composes a major scientific challenge. The present study, reviewed the current knowledge on the role of miRNA in pediatric CNS embryonal tumors, attempting to collect the existing information in one piece of work that could ideally be used as a guide for future reference and research.

Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS. 2007;115:1090–106.PubMed

Mirnezami AH, Pickard K, Zhang L, Primrose JN, Packham G. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol. 2009;35:339–47.PubMed

Singh SK, Pal Bhadra M, Girschick HJ, Bhadra U. MicroRNAs–micro in size but macro in function. FEBS J. 2008;275:4929–44.PubMed

Arunachalam G, Upadhyay R, Ding H, Triggle CR: MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol 2014; Nov 10 [Epub ahead of print].

Chang RC, Ying W, Bazer FW, Zhou B. MicroRNAs control macrophage formation and activation: the inflammatory link between obesity and cardiovascular diseases. Cells. 2014;3:702–12.PubMedCentralPubMed

Dorn 2nd GW. MicroRNAs in cardiac disease. Transl Res. 2011;157:226–35.PubMedCentralPubMed

Wang F, Chen C, Wang D: Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets. Front Med 2014; Dec 1. [Epub ahead of print].

Wang G, Zhao Y, Zheng Y. miR-122/Wnt/beta-catenin regulatory circuitry sustains glioma progression. Tumour Biol. 2014;35(9):8565–72.PubMed

Holm A, Bang-Berthelsen CH, Knudsen S, Modvig S, Kornum BR, Gammeltoft S, et al. miRNA profiles in cerebrospinal fluid from patients with central hypersomnias. J Neurol Sci. 2014;347:199–204.PubMed

10.

Deng X, Su Y, Wu H, Wu R, Zhang P, Dai Y, Chan TM, Zhao M, Lu Q: The role of microRNAs in autoimmune diseases with skin involvement. Scand J Immunol 2014; Nov 27. doi: 10.1111/sji.12261. [Epub ahead of print].

11.

Ha TY. MicroRNAs in human diseases: from autoimmune diseases to skin, psychiatric and neurodegenerative diseases. Immune Netw. 2011;11:227–44.PubMedCentralPubMed

12.

Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Ochi H, Hiraga N, Imamura M, Aikata H, Kawaoka T, et al.: Differences in serum microRNA profiles in hepatitis B and C virus infection. J Infect 2014.; Nov 5. doi: 10.1016/j.jinf.2014.10.017. [Epub ahead of print].

13.

Mohammad AA, Rahbar A, Lui WO, Davoudi B, Catrina A, Stragliotto G, et al. Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. PLoS One. 2014;9:e113740.PubMedCentralPubMed

14.

Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. J Cardiovasc Transl Res. 2012;5:413–22.PubMedCentralPubMed

15.

Karbiener M, Scheideler M. MicroRNA functions in brite/brown fat - novel perspectives towards anti-obesity strategies. Comput Struct Biotechnol J. 2014;11:101–5.PubMedCentralPubMed

16.

Vinnikov IA, Hajdukiewicz K, Reymann J, Beneke J, Czajkowski R, Roth LC, et al. Hypothalamic miR-103 protects from hyperphagic obesity in mice. J Neurosci. 2014;34:10659–74.PubMed

17.

Wang R, Cao YN, Hong J, Shi J, Gu W, Zhang YF, Wang W, Ning G: Elevated Circulating MicroRNA-122 Is Associated with Obesity and Insulin Resistance in Young Adults. Eur J Endocrinol 2014; Dec 16. [Epub ahead of print].

18.

Dong L, Wang X, Tan J, Li H, Qian W, Chen J, et al. Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med. 2014;18:2213–24.PubMedCentralPubMed

19.

Duroux-Richard I, Presumey J, Courties G, Gay S, Gordeladze J, Jorgensen C, et al. MicroRNAs as new player in rheumatoid arthritis. Joint Bone Spine. 2011;78:17–22.PubMed

20.

Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics. Biomark Res. 2014;2:19.PubMedCentralPubMed

21.

Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A. 2007;104:13513–8.PubMedCentralPubMed

22.

Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2011;585:2087–99.PubMed

23.

Bhattacharyya M, Nath J, Bandyopadhyay S. MicroRNA signatures highlight new breast cancer subtypes. Gene. 2014;556(2):192–8. doi:10.1016/j.gene.2014.11.053. Epub 2014 Dec 5.PubMed

24.

Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014;13:256.PubMedCentralPubMed

25.

Zhang K, Gao H, Wu X, Wang J, Zhou W, Sun G, et al. Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA. Clin Cancer Res. 2014;20:1179–89.PubMed

26.

Zhang ZG, Chen WX, Wu YH, Liang HF, Zhang BX. MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochem Biophys Res Commun. 2014;454:109–14.PubMed

27.

Canturk KM, Ozdemir M, Can C, Oner S, Emre R, Aslan H, Cilingir O, Ciftci E, Celayir FM, Aldemir O, et al.: Investigation of key miRNAs and target genes in bladder cancer using miRNA profiling and bioinformatic tools. Mol Biol Rep 2014. [Epub ahead of print].

28.

Chiyomaru T, Seki N, Inoguchi S, Ishihara T, Mataki H, Matsushita R, et al. Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. Int J Oncol. 2014;46(2):487–96. doi: 10.3892/ijo.2014.2752. Epub 2014 Nov 14.PubMedCentralPubMed

29.

Xiu Y, Liu Z, Xia S, Jin C, Yin H, Zhao W, et al. MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3. PLoS One. 2014;9:e109734.PubMedCentralPubMed

30.

Badal SS, Danesh FR: MicroRNAs and their applications in kidney diseases. Pediatr Nephrol 2014; Jun 14. [Epub ahead of print]

31.

Hohenstein P, Hastie ND. LINking microRNAs, kidney development, and Wilms tumors. Genes Dev. 2014;28:923–5.PubMedCentralPubMed

32.

Lichner Z, Saleh C, Subramaniam V, Seivwright A, Prud’homme GJ, Yousef GM: miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties. Oncotarget 2014; Apr 16. [Epub ahead of print].

33.

Zaravinos A, Lambrou GI, Mourmouras N, Katafygiotis P, Papagregoriou G, Giannikou K, et al. New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney. PLoS One. 2014;9:e91646.PubMedCentralPubMed

34.

Fuchs E, Segre JA. Stem cells: a new lease on life. Cell. 2000;100:143–55.PubMed

35.

Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell. 2000;100:157–68.PubMed

36.

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.PubMed

37.

Pantic I. Cancer stem cell hypotheses: impact on modern molecular physiology and pharmacology research. J Biosci. 2011;36:957–61.PubMed

38.

Buzanska L, Spassky N, Belin MF, Giangrande A, Guillemot F, Klambt C, et al. Human medulloblastoma cell line DEV is a potent tool to screen for factors influencing differentiation of neural stem cells. J Neurosci Res. 2001;65:17–23.PubMed

39.

Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res. 1992;52:5334–41.PubMed

40.

Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895–902.PubMed

41.

Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004;23:7267–73.PubMed

42.

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.PubMed

43.

Tohyama T, Lee VM, Rorke LB, Marvin M, McKay RD, Trojanowski JQ. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest. 1992;66:303–13.PubMed

44.

Lambrou GI, Remboutsika E. Proliferation versus regeneration: the good, the bad and the ugly. Front Physiol. 2014;5:10.PubMedCentralPubMed

45.

Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer. 2008;112:416–32.PubMed

46.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.PubMedCentralPubMed

47.

Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT’91. Clin Cancer Res. 2007;13:2651–7.PubMed

48.

Ellison DW. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol. 2010;120:305–16.PubMed

49.

Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381–96.PubMedCentralPubMed

50.

Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27:1627–36.PubMed

51.

Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol. 2010;120:553–66.PubMed

52.

Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408–14.PubMed

53.

Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet. 2011;204:577–88.PubMed

54.

Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol. 2013;15:1644–51.PubMedCentralPubMed

55.

Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res. 2005;65:703–7.PubMed

56.

Saylors 3rd RL, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B, et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991;51:4721–3.PubMed

57.

Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, et al. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol. 2013;15:83–90.PubMedCentralPubMed

58.

Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008;90:1–7.PubMed

59.

Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, et al. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol. 2009;40:1234–43.PubMed

60.

Xu QF, Pan YW, Li LC, Zhou Z, Huang QL, Pang JC, et al. MiR-22 is Frequently Downregulated in Medulloblastomas and Inhibits Cell Proliferation via the Novel Target PAPST1. Brain Pathol. 2014;24(6):568–83. doi:10.1111/bpa.12136. Epub 2014 Apr 15.PubMed

61.

Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle. 2010;9:1809–18.PubMed

62.

Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008;27:2616–27.PubMedCentralPubMed

63.

Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, et al. The miR-17 ~ 92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A. 2009;106:2812–7.PubMedCentralPubMed

64.

Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424–30.PubMedCentralPubMed

65.

Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S, et al. Silencing of the miR-17 ~ 92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013;73:7068–78.PubMed

66.

Zindy F, Kawauchi D, Lee Y, Ayrault O, Ben Merzoug L, McKinnon PJ, et al. Role of the miR-17 approximately 92 cluster family in cerebellar and medulloblastoma development. Biol Open. 2014;3:597–605.PubMedCentralPubMed

67.

Bai AH, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, et al. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012;123:529–38.PubMed

68.

Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther. 2010;6:521–9.PubMed

69.

Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One. 2009;4:e4998.PubMedCentralPubMed

70.

Fiaschetti G, Abela L, Nonoguchi N, Dubuc AM, Remke M, Boro A, et al. Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. Br J Cancer. 2014;110:636–47.PubMedCentralPubMed

71.

Andolfo I, Liguori L, De Antonellis P, Cusanelli E, Marinaro F, Pistollato F, et al. The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. Neuro Oncol. 2012;14:596–612.PubMedCentralPubMed

72.

Pang JC, Kwok WK, Chen Z, Ng HK. Oncogenic role of microRNAs in brain tumors. Acta Neuropathol. 2009;117:599–611.PubMed

73.

Grunder E, D’Ambrosio R, Fiaschetti G, Abela L, Arcaro A, Zuzak T, et al. MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur J Cancer. 2011;47:2479–90.PubMed

74.

Vo DT, Qiao M, Smith AD, Burns SC, Brenner AJ, Penalva LO. The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol. 2011;8:817–28.PubMed

75.

Li KK, Xia T, Ma FM, Zhang R, Mao Y, Wang Y, Zhou L, Lau KM, Ng HK: miR-106b is overexpressed in medulloblastomas and interacts directly with PTEN. Neuropathol Appl Neurobiol 2014; Jul 8. doi:10.1111/nan.12169. [Epub ahead of print].

76.

Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, et al. MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009;124:568–77.PubMed

77.

Venkataraman S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR, et al. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem. 2013;288:1918–28.PubMedCentralPubMed

78.

Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One. 2010;5:e10748.PubMedCentralPubMed

79.

Takwi AA, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park AK, et al. A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med. 2012;4:896–909.PubMedCentralPubMed

80.

Lu Y, Ryan SL, Elliott DJ, Bignell GR, Futreal PA, Ellison DW, et al. Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One. 2009;4:e6159.PubMedCentralPubMed

81.

Liu W, Gong YH, Chao TF, Peng XZ, Yuan JG, Ma ZY, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas. Chin Med J (Engl). 2009;122:2405–11.

82.

Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle. 2010;9:1031–6.PubMedCentralPubMed

83.

de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011;6:e24584.PubMedCentralPubMed

84.

Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011;13:165–75.PubMedCentralPubMed

85.

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2011;56:211–6.PubMed

86.

Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, et al. Pleiotropic effects of miR-183 ~ 96 ~ 182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012;123:539–52.PubMed

87.

Zhang Z, Li S, Cheng SY. The miR-183 approximately 96 approximately 182 cluster promotes tumorigenesis in a mouse model of medulloblastoma. J Biomed Res. 2013;27:486–94.PubMedCentralPubMed

88.

Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, et al. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2013;23:413–25.PubMed

89.

Asuthkar S, Velpula KK, Nalla AK, Gogineni VR, Gondi CS, Rao JS. Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene. 2014;33:1922–33.PubMed

90.

Shi J, Yang L, Wang T, Zhang J, Guo X, Huo X, et al. miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. Mol Med Rep. 2013;8:1111–7.PubMed

91.

Jin Y, Xiong A, Zhang Z, Li S, Huang H, Yu TT, et al. MicroRNA-31 suppresses medulloblastoma cell growth by inhibiting DNA replication through minichromosome maintenance 2. Oncotarget. 2014;5:4821–33.PubMedCentralPubMed

92.

Pannuru P, Dontula R, Khan AA, Herbert E, Ozer H, Chetty C, et al. miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells. Cell Signal. 2014;26:2193–201.PubMed

93.

Biegel JA, Rorke LB, Janss AJ, Sutton LN, Parmiter AH. Isochromosome 17q demonstrated by interphase fluorescence in situ hybridization in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer. 1995;14:85–96.PubMed

94.

Biegel JA, Rorke LB, Packer RJ, Sutton LN, Schut L, Bonner K, et al. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer. 1989;1:139–47.PubMed

95.

Blaeker H, Rasheed BK, McLendon RE, Friedman HS, Batra SK, Fuchs HE, et al. Microsatellite analysis of childhood brain tumors. Genes Chromosomes Cancer. 1996;15:54–63.PubMed

96.

Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997;57:4042–7.PubMed

97.

Avet-Loiseau H, Venuat AM, Terrier-Lacombe MJ, Lellouch-Tubiana A, Zerah M, Vassal G. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer. 1999;79:1843–7.PubMedCentralPubMed

98.

Nicholson JC, Ross FM, Kohler JA, Ellison DW. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer. 1999;80:1322–31.PubMedCentralPubMed

99.

Russo C, Pellarin M, Tingby O, Bollen AW, Lamborn KR, Mohapatra G, et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer. 1999;86:331–9.PubMed

100.

Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, et al. A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol. 2014;16:62–71.PubMedCentralPubMed

101.

Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, et al. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol. 2012;124:875–81.PubMedCentralPubMed

102.

Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009;16:533–46.PubMedCentralPubMed

103.

Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, et al. miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int. 2013;13:21.PubMedCentralPubMed

104.

Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I. The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int. 2013;29:101–19.PubMedCentralPubMed

105.

Spence T, Sin-Chan P, Picard D, Barszczyk M, Hoss K, Lu M, et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014;128:291–303.PubMedCentralPubMed

106.

Archer TC, Pomeroy SL. A developmental program drives aggressive embryonal brain tumors. Nat Genet. 2014;46:2–3.PubMed

107.

Gerber NU, von Hoff K, von Bueren AO, Treulieb W, Warmuth-Metz M, Pietsch T, et al. Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. J Neurooncol. 2011;102:459–69.PubMed

108.

Rickert CH, Hasselblatt M. Cytogenetic features of ependymoblastomas. Acta Neuropathol. 2006;111:559–62.PubMed

109.

Nobusawa S, Yokoo H, Hirato J, Kakita A, Takahashi H, Sugino T, et al. Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol. 2012;22:689–97.PubMed

110.

Koff A. How to decrease p27Kip1 levels during tumor development. Cancer Cell. 2006;9:75–6.PubMed

111.

Sredni ST, Bonaldo Mde F, Costa FF, Huang CC, Hamm CA, Rajaram V, et al. Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nerv Syst. 2010;26:279–83.PubMed

112.

Grupenmacher AT, Halpern AL, Bonaldo Mde F, Huang CC, Hamm CA, de Andrade A, et al. Study of the gene expression and microRNA expression profiles of malignant rhabdoid tumors originated in the brain (AT/RT) and in the kidney (RTK). Childs Nerv Syst. 2013;29:1977–83.PubMed

113.

Lee YY, Yang YP, Huang MC, Wang ML, Yen SH, Huang PI, et al. MicroRNA142-3p promotes tumor-initiating and radioresistant properties in malignant pediatric brain tumors. Cell Transplant. 2014;23:669–90.PubMed

114.

de Planell-Saguer M, Rodicio MC. Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta. 2011;699:134–52.PubMed

115.

Shalaby T, Fiaschetti G, Baumgartner M, Grotzer MA. MicroRNA Signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons. Int J Mol Sci. 2014;15:21554–86.PubMedCentralPubMed

116.

Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165–73.PubMed

117.

Uso M, Jantus-Lewintre E, Sirera R, Bremnes RM, Camps C. miRNA detection methods and clinical implications in lung cancer. Future Oncol. 2014;10:2279–92.PubMed

118.

Ban E, Song EJ. Capillary electrophoresis methods for microRNAs assays: a review. Anal Chim Acta. 2014;852C:1–7.

119.

Wang N, Zhou Z, Liao X, Zhang T. Role of microRNAs in cardiac hypertrophy and heart failure. IUBMB Life. 2009;61:566–71.PubMed

120.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–4.PubMed

121.

Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613–8.PubMed

122.

Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775–89.PubMedCentralPubMed

123.

Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172:962–74.PubMedCentralPubMed

124.

Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol. 2010;20:R858–61.PubMedCentralPubMed

125.

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–6.PubMed

126.

Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29:1580–7.PubMedCentralPubMed

127.

Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005–17.PubMedCentralPubMed

128.

Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–30.PubMedCentralPubMed

129.

Chen ZY, Liang K, Qiu RX, Luo LP. Enhancing microRNA transfection to inhibit survivin gene expression and induce apoptosis: could it be mediated by a novel combination of sonoporation and polyethylenimine? Chin Med J (Engl). 2011;124:3592–4.

130.

Strotbek M, Florin L, Koenitzer J, Tolstrup A, Kaufmann H, Hausser A, et al. Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells. Metab Eng. 2013;20:157–66.PubMed

131.

Diaz MR, Vivas-Mejia PE. Nanoparticles as drug delivery systems in cancer medicine: emphasis on RNAi-containing nanoliposomes. Pharmaceuticals (Basel). 2013;6:1361–80.

132.

Deeken JF, Loscher W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13:1663–74.PubMed

133.

Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46:298–311.PubMed

134.

Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011;286:19127–37.PubMedCentralPubMed

135.

Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008;283:33394–405.PubMedCentralPubMed

136.

Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013;93:98–104.PubMed

Title: MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown
Authors: Maria Braoudaki
George I Lambrou
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-014-0101-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society

Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A

IGF-IR determines the fates of BCR/ABL leukemia

High expression of neuroguidin increases the sensitivity of acute myeloid leukemia cells to chemotherapeutic drugs

Notch1 phenotype and clinical stage progression in non-small cell lung cancer

TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer